Lantern Pharma Inc Ordinary Shares LTRN

Morningstar Rating
$2.87 −0.04 (1.37%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

LTRN is trading at a LOCK|Wt^<n premium.
Price
$2.87
Fair Value
LOCK|T>&$<
Uncertainty
LOCK|!? G%Dz
1-Star Price
LOCK|$&!m?
5-Star Price
LOCK|#ytWt$n
Economic Moat
LOCK|$Zf
Capital Allocation

Trading Information

Previous Close Price
$2.91
Day Range
$2.803.05
52-Week Range
$1.115.74
Bid/Ask
$2.85 / $3.40
Shares Outstanding
12.76M
Market Cap
$36.62M
Volume/Avg
106,247 / 242,069

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield

Company Profile

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
16

Valuation

Metric
LTRN
Price/Earnings (Normalized)
Price/Book Value
9.37
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
LTRN
Quick Ratio
1.67
Current Ratio
1.87
Interest Coverage
Quick Ratio
LTRN

Profitability

Metric
LTRN
Return on Assets (Normalized)
−109.00%
Return on Equity (Normalized)
−157.05%
Return on Invested Capital (Normalized)
−158.57%
Return on Assets
LTRN

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|S?^Q#&?LOCK|$n&#$123B
Regeneron Pharmaceuticals Inc
REGN
LOCK|&ZC$C>%LOCK|%pYn$71B
argenx SE ADR
ARGX
LOCK|%YfbyM$LOCK|z^<$54B
BeOne Medicines Ltd ADR
ONC
LOCK|v>k&%Z$LOCK|q$?$36B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|<!!VTd>LOCK|?PjN$36B
Royalty Pharma PLC Class A
RPRX
LOCK|dQG^jGV&LOCK|s!F@$26B
Moderna Inc
MRNA
LOCK|RgQxh&FLOCK|?!$25B
Incyte Corp
INCY
LOCK|ksSC%qnLOCK|QJf$23B
BioNTech SE ADR
BNTX
LOCK|#!r?GbLOCK|T>!$23B
BridgeBio Pharma Inc
BBIO
LOCK|s^Yj<qwLOCK|#JR$16B

Sponsor Center